title: Prevalence of Helicobacter pylori infection measured with urinary antibody in an urban area of Japan, 2008-2010.
abstract: Helicobacter pylori (H. pylori) has expanded to infect about half the world's population. Although there were many studies on the prevalence of H. pylori infection for defined areas in the 1990s throughout the world, there were only limited sources tracking its latest prevalence among large populations. In the present study, we estimated the prevalence of H. pylori among the inhabitants of Nagoya, an urban area of Japan. Study subjects were 5167 participants (1467 males and 3700 females) aged 35 to 69 years from the Daiko Study, a part of the Japan Multi-Institutional Collaborative Cohort Study (J-MICC Study). A urinary anti-H. pylori antibody was used to detect H. pylori infection. The history of eradication treatments for H. pylori infection was obtained using self-administered questionnaires. The prevalence detected by the urinary test included 19.6% (95% confidence interval; 16.8-22.6%) for those aged 35-39 years, 25.8% (23.5-28.2%) for 40-49 years, 39.4% (36.8-42.1%) for 50-59 years, 50.3% (47.8-52.7%) for 60-69 years, and 36.4% (35.1-37.7%). Among 5167 participants, 266 (5.1%) stated that they had received an eradication treatment. Since 167 subjects with negative urinary tests replied that they had been seropositive for H. pylori in the past, they were included among the ever-infected inhabitant group. Consequently, the overall rate of those with a history of persistent infection was 39.6% (38.3-40.9%). The prevalence of H. pylori infection observed in Nagoya seemed to be lower than the corresponding prevalence reported in other studies of Japan. That lower rate might be due to the reduced exposure from improved urban sanitary conditions.
authors.affiliation: Department of Preventive Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. takashi.tamura@c.mbox.nagoya-u.ac.jp
authors.forename: Takashi
authors.initials: T
authors.lastname: Tamura
authors.forename: Emi
authors.initials: E
authors.lastname: Morita
authors.forename: Takaaki
authors.initials: T
authors.lastname: Kondo
authors.forename: Jun
authors.initials: J
authors.lastname: Ueyama
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tanaka
authors.forename: Yuto
authors.initials: Y
authors.lastname: Kida
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hori
authors.forename: Shigeru
authors.initials: S
authors.lastname: Inoue
authors.forename: Koutaro
authors.initials: K
authors.lastname: Tomita
authors.forename: Rieko
authors.initials: R
authors.lastname: Okada
authors.forename: Sayo
authors.initials: S
authors.lastname: Kawai
authors.forename: Asahi
authors.initials: A
authors.lastname: Hishida
authors.forename: Mariko
authors.initials: M
authors.lastname: Naito
authors.forename: Kenji
authors.initials: K
authors.lastname: Wakai
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Hamajima
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000652:urine*; D015415:Biomarkers / Q000652:urine; D005260:Female; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology / Q000652:urine; D016480:Helicobacter pylori / Q000276:immunology*; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015995:Prevalence; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014504:Urban Health / Q000706:statistics & numerical data*; D016482:Urinalysis
chemical_list: D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D015415:Biomarkers